Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus H7N9 vaccine nanopatch - Vaxxas

Next Previous
X
Search
Drug Profile

Influenza A virus H7N9 vaccine nanopatch - Vaxxas

Alternative Names: Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine - Vaxxas

Latest Information Update: 05 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxxas
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Influenza A virus H7N9 subtype

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 31 Jul 2024 Phase-I clinical trials in Influenza A virus H7N9 subtype (Prevention) in Australia (Transdermal) (NCT06417853)
  • 23 May 2024 Vaxxas plans a phase I HD-MAP trial in Healthy adults volunteers (Prevention) in Australia in July 2024 (Intradermal, Patch) (NCT06417853)
  • 13 Apr 2021 Influenza A virus H7N9 vaccine nanopatch - Vaxxas is available for licensing as of 13 Apr 2021. https://www.vaxxas.com/contact-us/ (Vaxxas website, April 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top